VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2022 | Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphoma

Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, discusses the importance of novel immunotherapies, including CAR-T cell therapy and bispecific antibodies, for the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). Prof. Carlo-Stella then shares some results from a Phase I/II study evaluating glofitamab monotherapy in patients with R/R MCL (NCT03075696), commenting on the high response rates observed and the value of this agent in the MCL treatment landscape. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


AstraZeneca: Honoraria; Sanofi: Other: Consultancy/Advisory, Research Funding; Bristol Myers Squibb: Honoraria; Merck Sharp & Dohme: Honoraria; Takeda: Honoraria; Novartis: Honoraria; Incyte: Honoraria; Janssen Oncology: Honoraria; Celgene/Bristol Myers Squibb: Other: Consultancy/Advisory; Roche: Other: Consultancy/Advisory, Research Funding; ADC Therapeutics: Honoraria, Other: Consultancy/Advisory, Research Funding; Karyopharm Therapeutics: Other: Consultancy/Advisory; Scenic Biotech: Other: Consultancy/Advisory.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter